top of page

Dear Valued Patient,


We are writing to inform you of an important update regarding compounded tirzepatide. The U.S. Food and Drug Administration (FDA) has removed tirzepatide from its drug shortage list. As a result, compounded tirzepatide will no longer be available unless further guidance is issued by the FDA.


Please note that this is an evolving situation, and the current guidance is subject to change. We are committed to keeping you informed and will promptly share any updates regarding this situation.


If you would like to order compounded tirzepatide, we can accept orders until Thursday February 13th @ 4pm. Please notify us as soon as possible via text or email if you would like to place an order. Please ensure you receive confirmation from us that your order is being processed.


Note regarding vials: Injection supplies will no longer be included. We recommend purchasing the following supplies: 
•    Syringes 
•    Alcohol Wipes

​

After February 13th, here are your options...


1. Discontinue Medication:

If you would like to discontinue medication, please notify us so we can assist you with tapering off safely.


2. Talk with Your PCP:

Consult your primary care provider (PCP) about ordering the brand-name medication and exploring insurance coverage options. Previously, insurers typically covered this medication for type 2 diabetes. Recently we have been told that some are covering for sleep apnea as well.  


3. Transition to Semaglutide Injections:

Semaglutide is a single GLP-1 peptide. Some individuals experience more gastrointestinal (GI) side effects with this medication, but this usually subsides over time, and we have tools to help overcome any GI side effects. Most compounded semaglutide has a 90-day expiration and includes B12. Please inform us if you prefer a version without B12. The maximum dose for injectable Semaglutide is 2.5mg per week.


Recommended Dosing Adjustments:
o    Currently taking 2.5 mg weekly: Transition to 0.5 mg weekly.
o    Currently taking 5 mg weekly: Transition to 1 mg weekly.
o    Currently taking 7.5 mg weekly: Transition to 1.5 mg weekly.
Note:  Dosing titration may be needed based on your response to the medication.


4. Transition to Oral Tirzepatide:
Oral tirzepatide is very new, with limited studies available.


Recommended Dosing Adjustments: 
o    Currently taking 2.5 mg weekly: Transition to 3 mg daily.
o    Currently taking 5 mg weekly: Transition to 6 mg daily.
o    Currently taking 7.5 mg weekly: Transition to 12 mg daily.
Dosing titration may be needed based on your response to the medication.


5. Transition to Oral Semaglutide:
Oral semaglutide has been available for a few years, with several studies supporting its efficacy.

 

Recommended Dosing Adjustments:
o    Currently taking 2.5 mg weekly: Transition to 2 mg daily.
o    Currently taking 5 mg weekly: Transition to 4 mg daily.
o    Currently taking 7.5 mg weekly: Transition to 8 mg daily.
Dosing titration may be needed based on your response to the medication.


We understand that this change may raise questions or concerns about your treatment plan, and we are here to support you through this transition and discuss alternative options as needed. It may help to know that my recommendation would be to transition to semaglutide injections for those who are not ready to discontinue medication and cannot get GLP1 medication through insurance.

​

We truly appreciate your patience as we navigate these changes.
Thank you for your understanding and continued trust in our care.


Sincerely,
Amber Woken, NP
 

bottom of page